Form 10-Q · Quarterly report
Biogen 10-Q, filed Jul 29, 2026
- Filed
- CIK
- 0000875045
- Accession no.
- 0000875045-26-000075
Summary
Biogen completed its acquisition of Apellis on May 14, 2026, adding SYFOVRE for geographic atrophy and EMPAVELI for PNH, C3G and primary IC-MPGN. Biogen also said it expects continued TECFIDERA revenue declines after the European Patent Office revoked a related patent in November 2025, and it described new U.S. tariffs, including a 100% tariff on imports of patented pharmaceuticals and biologics, as creating uncertainty.
Key points
- Biogen completed its acquisition of Apellis on May 14, 2026, adding SYFOVRE for geographic atrophy and EMPAVELI for PNH, C3G and primary IC-MPGN.
- The European Patent Office revoked Biogen's EP 2 653 873 patent related to TECFIDERA in November 2025, and multiple generic entrants are now in North America, Brazil and the EU.
- The U.S. Administration imposed a 100% tariff on imports of patented pharmaceuticals, biologics and associated ingredients, effective for certain categories on July 31, 2026, and others on September 29, 2026.
- Biogen's Solothurn, Switzerland manufacturing facility is operational and approved for the manufacture of LEQEMBI and TYSABRI.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION EXECUTIVE SUMMARY INTRODUCTION Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We are focused on advancing our pipeline, including significant late stage programs, in neurology, specialized immunology and rare diseases across multiple modalities. Our drug discovery and development efforts are supported by internal research and development programs, external collaborations and acquisitions of businesses and assets. Our marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.